Evelo Biosciences Stock Performance
| EVLO Stock | USD 0.0005 0.0004 400.00% |
Evelo Biosciences holds a performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -13.68, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Evelo Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, Evelo Biosciences is expected to outperform it. Use Evelo Biosciences total risk alpha, as well as the relationship between the accumulation distribution and price action indicator , to analyze future returns on Evelo Biosciences.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Evelo Biosciences are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent essential indicators, Evelo Biosciences displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 69.8 M | |
| Total Cashflows From Investing Activities | -622 K |
Evelo |
Evelo Biosciences Relative Risk vs. Return Landscape
If you would invest 0.02 in Evelo Biosciences on December 4, 2025 and sell it today you would earn a total of 0.03 from holding Evelo Biosciences or generate 150.0% return on investment over 90 days. Evelo Biosciences is currently generating 10.4918% in daily expected returns and assumes 73.2445% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Evelo, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evelo Biosciences Target Price Odds to finish over Current Price
The tendency of Evelo Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0005 | 90 days | 0.0005 | about 10.08 |
Based on a normal probability distribution, the odds of Evelo Biosciences to move above the current price in 90 days from now is about 10.08 (This Evelo Biosciences probability density function shows the probability of Evelo Pink Sheet to fall within a particular range of prices over 90 days) .
Evelo Biosciences Price Density |
| Price |
Predictive Modules for Evelo Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Evelo Biosciences. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Evelo Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Evelo Biosciences is not an exception. The market had few large corrections towards the Evelo Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Evelo Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Evelo Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 9.28 | |
β | Beta against Dow Jones | -13.68 | |
σ | Overall volatility | 0.0002 | |
Ir | Information ratio | 0.12 |
Evelo Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Evelo Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Evelo Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Evelo Biosciences is way too risky over 90 days horizon | |
| Evelo Biosciences has some characteristics of a very speculative penny stock | |
| Evelo Biosciences appears to be risky and price may revert if volatility continues | |
| Evelo Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (114.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Evelo Biosciences currently holds about 92.01 M in cash with (101.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are held by institutions such as insurance companies |
Evelo Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Evelo Pink Sheet often depends not only on the future outlook of the current and potential Evelo Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Evelo Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.4 M | |
| Cash And Short Term Investments | 47.9 M |
Evelo Biosciences Fundamentals Growth
Evelo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Evelo Biosciences, and Evelo Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evelo Pink Sheet performance.
| Return On Equity | -62.33 | |||
| Return On Asset | -0.83 | |||
| Current Valuation | 23.69 M | |||
| Shares Outstanding | 18.93 M | |||
| Price To Earning | (4.19) X | |||
| Price To Book | 3.51 X | |||
| EBITDA | (108.41 M) | |||
| Cash And Equivalents | 92.01 M | |||
| Cash Per Share | 0.85 X | |||
| Total Debt | 51.14 M | |||
| Debt To Equity | 1.55 % | |||
| Book Value Per Share | (1.42) X | |||
| Cash Flow From Operations | (101.23 M) | |||
| Earnings Per Share | (15.64) X | |||
| Total Asset | 64.44 M | |||
| Retained Earnings | (529.22 M) | |||
| Current Asset | 49.29 M | |||
| Current Liabilities | 4.32 M | |||
About Evelo Biosciences Performance
By examining Evelo Biosciences' fundamental ratios, stakeholders can obtain critical insights into Evelo Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Evelo Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Evelo Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.Things to note about Evelo Biosciences performance evaluation
Checking the ongoing alerts about Evelo Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Evelo Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evelo Biosciences is way too risky over 90 days horizon | |
| Evelo Biosciences has some characteristics of a very speculative penny stock | |
| Evelo Biosciences appears to be risky and price may revert if volatility continues | |
| Evelo Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (114.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Evelo Biosciences currently holds about 92.01 M in cash with (101.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Evelo Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evelo Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Evelo Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evelo Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evelo Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evelo Biosciences' pink sheet. These opinions can provide insight into Evelo Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Evelo Pink Sheet
Evelo Biosciences financial ratios help investors to determine whether Evelo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evelo with respect to the benefits of owning Evelo Biosciences security.